LFB completed the acquisition of Amber Plasma from Dibiti.

LFB, a biopharmaceutical group, completed the acquisition of Amber Plasma, a company specializing in the collection of plasma for medical use, from Dibiti, a Czech investment fund. Financial terms were not disclosed. “We are happy to welcome all employees from Amber Plasma to LFB. We look forward to working together in serving more and more patients with plasma-derived therapies, including in the Czech Republic. This is an important milestone in our effort to bring additional plasma for fractionation to our new industrial French site in Arras which will triple the production capacity for LFB’s medicines. It is a major step forward for patients living with these serious and often rare diseases. As well we are also pleased to welcome all plasma donors from Amber Plasma with their essential contribution at the start of the long-lasting process to produce the so urgently needed medicines,” Jacques Brom, LFB CEO.